Research Only
Retatrutide 15mg AQ Pen
What the research shows
- 25.0% average weight loss in 80 weeks
- 1.94% average HbA1c drop in 40 weeks
- 82.4% average liver-fat reduction in 24 weeks
Published study results for the compound, not results from this product. For research use only.
Retatrutide is an investigational single-molecule agonist of the GIP, GLP-1 and glucagon receptors, studied in controlled clinical research. This separate 3mL Genovare pen is labelled 15mg and is not presented as sponsor-supplied trial material or an authorised medicine. No batch-specific independent report is linked, so sequence, identity, quantity and purity are unverified.
Compound: Retatrutide
Catalogue strength: 15 mg
Format: Aqueous pre-filled pen
Storage: Follow the Genovare package label.
- Pack Size
- 3mL
- Product details
- Genovare Catalogue
- Pre-Filled Pen
- Premixed Aqueous
- Storage Guidance
- Follow Package Label
What Is Included
- 1 pre-filled Genovare research pen
- 3 pen needles
- Genovare retail packaging
Genovare Pre-Filled Pen Premixed Aqueous
SpecsRetatrutide 15mg AQ Pen
Triple-receptor agonist tested in phase 3 trials
AED 550 / pen
Restock Alert
Get an email when it is back
- Sold by
- Remy Research
- Brand
- Genovare
- Manufacturer
- Genovare
- Tested by
- Independent testing not supplied
Also available
Ships from Dubai
Janoshik report
Remedium Research 30mg Retatrutide FlexiPen
· AED 800–1,600/pen
In stock
ZPHC Retatrutide AQ 30mg / 3mL Pen
· AED 1,440/pen
In stock
Genovare Retatrutide 30mg AQ Pen
· AED 900/pen
In stock
Genovare RETAKLIK 2.0 Retatrutide + Cagrilintide 35mg Total (30mg + 5mg) AQ Pen
· AED 1,200/pen
Technical Specifications
| Manufacturer | Genovare |
|---|---|
| Compound | Retatrutide |
| Catalogue strength | 15 mg |
| Fill volume | 3mL |
| Format | Aqueous pre-filled pen |
| Pack size | 1 pen with 3 needles |
| Independent testing | Not supplied |
Overview
Batch proof